Regulated information April 22, 2013 TiGenix reports positive Phase IIa study results in refractory rheumatoid arthritis with allogeneic stem cell product Cx611 Management will conduct a conference call to discuss the results today at 4pm CET, 10am EST Dial-in numbers are provided at the end of this press release Leuven - April 22, 2013 - TiGenix , ... (more)
http://www.pr-inside.com/tigenix-positive-phase-iia-study-results-in-refrac-r3645135.htm
http://www.pr-inside.com/tigenix-positive-phase-iia-study-results-in-refrac-r3645135.htm
No comments:
Post a Comment